HRP20030383B1 - Lactam compound - Google Patents

Lactam compound

Info

Publication number
HRP20030383B1
HRP20030383B1 HR20030383A HRP20030383A HRP20030383B1 HR P20030383 B1 HRP20030383 B1 HR P20030383B1 HR 20030383 A HR20030383 A HR 20030383A HR P20030383 A HRP20030383 A HR P20030383A HR P20030383 B1 HRP20030383 B1 HR P20030383B1
Authority
HR
Croatia
Prior art keywords
lactam compound
methyl
compound
benzazepin
alanyl
Prior art date
Application number
HR20030383A
Other languages
English (en)
Croatian (hr)
Inventor
Edmund Audia James
Varghese John
H. Latimer Lee
Leigh Mcdaniel Stacey
Scott Nissen Jeffrey
D. Thorsett Eugene
S. Tung Jay
Original Assignee
Eli Lilly And Company
Elan Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, Elan Pharmaceuticals filed Critical Eli Lilly And Company
Publication of HRP20030383A2 publication Critical patent/HRP20030383A2/xx
Publication of HRP20030383B1 publication Critical patent/HRP20030383B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20030383A 2000-11-17 2003-05-14 Lactam compound HRP20030383B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (en) 2000-11-17 2001-11-05 Lactam compound to inhibit beta-amyloid peptide release or synthesis

Publications (2)

Publication Number Publication Date
HRP20030383A2 HRP20030383A2 (en) 2005-10-31
HRP20030383B1 true HRP20030383B1 (en) 2007-12-31

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030383A HRP20030383B1 (en) 2000-11-17 2003-05-14 Lactam compound

Country Status (34)

Country Link
US (1) US20050261495A1 (xx)
EP (1) EP1341531B1 (xx)
JP (1) JP4116437B2 (xx)
KR (1) KR100819679B1 (xx)
CN (1) CN1486184A (xx)
AR (1) AR035927A1 (xx)
AU (2) AU2002243192B2 (xx)
BR (1) BR0115427A (xx)
CA (1) CA2427227C (xx)
CY (1) CY1106366T1 (xx)
CZ (1) CZ20031351A3 (xx)
DE (1) DE60126132T2 (xx)
DK (1) DK1341531T3 (xx)
DZ (1) DZ3453A1 (xx)
EA (1) EA005954B1 (xx)
EC (1) ECSP034600A (xx)
ES (1) ES2278804T3 (xx)
HK (1) HK1059731A1 (xx)
HR (1) HRP20030383B1 (xx)
HU (1) HU228117B1 (xx)
IL (2) IL155960A0 (xx)
MX (1) MXPA03004292A (xx)
MY (1) MY134559A (xx)
NO (1) NO324324B1 (xx)
NZ (1) NZ525854A (xx)
PE (1) PE20020802A1 (xx)
PL (1) PL212199B1 (xx)
PT (1) PT1341531E (xx)
SI (1) SI1341531T1 (xx)
SK (1) SK288065B6 (xx)
TW (1) TWI305204B (xx)
UA (1) UA74849C2 (xx)
WO (1) WO2002047671A2 (xx)
ZA (1) ZA200303789B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
JP5039543B2 (ja) 2005-04-08 2012-10-03 第一三共株式会社 ピリジルメチルスルホン誘導体
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
PA8789701A1 (es) * 2007-07-16 2009-04-23 Wyeth Corp Inhibidores de producción de beta amiloide
EA017286B1 (ru) 2007-08-14 2012-11-30 Эли Лилли Энд Компани Ингибиторы гамма-секретазы
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP3970725A1 (en) 2012-09-07 2022-03-23 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2014171434A1 (ja) 2013-04-19 2014-10-23 国立大学法人岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
EP3458076A4 (en) 2016-05-16 2020-01-22 The General Hospital Corporation HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335583A (en) * 1996-12-23 2001-03-30 Lilly Co Eli Cycloalkyl, lactam, lactone and analogs, and pharmaceutical compositions
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
CA2425558C (en) * 2000-11-17 2012-01-03 Eli Lilly And Company Lactam compound
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam

Also Published As

Publication number Publication date
DZ3453A1 (fr) 2002-06-20
DE60126132T2 (de) 2007-10-18
AU4319202A (en) 2002-06-24
WO2002047671A2 (en) 2002-06-20
HK1059731A1 (en) 2004-07-16
PT1341531E (pt) 2007-04-30
HRP20030383A2 (en) 2005-10-31
EA200300580A1 (ru) 2003-10-30
EP1341531B1 (en) 2007-01-17
CY1106366T1 (el) 2011-10-12
MXPA03004292A (es) 2004-02-12
NO20032236D0 (no) 2003-05-16
TWI305204B (en) 2009-01-11
KR20030051846A (ko) 2003-06-25
US20050261495A1 (en) 2005-11-24
DE60126132D1 (de) 2007-03-08
PL212199B1 (pl) 2012-08-31
NO20032236L (no) 2003-07-10
JP4116437B2 (ja) 2008-07-09
HU228117B1 (en) 2012-11-28
CN1486184A (zh) 2004-03-31
UA74849C2 (en) 2006-02-15
CZ20031351A3 (cs) 2003-11-12
BR0115427A (pt) 2003-10-07
AU2002243192B2 (en) 2006-07-20
EA005954B1 (ru) 2005-08-25
HUP0301842A2 (hu) 2003-09-29
WO2002047671A3 (en) 2003-03-06
NO324324B1 (no) 2007-09-24
SK288065B6 (sk) 2013-04-03
IL155960A0 (en) 2003-12-23
SK5592003A3 (en) 2003-12-02
SI1341531T1 (sl) 2007-06-30
CA2427227A1 (en) 2002-06-20
CA2427227C (en) 2010-08-17
PE20020802A1 (es) 2002-09-10
ECSP034600A (es) 2003-06-25
JP2004517090A (ja) 2004-06-10
KR100819679B1 (ko) 2008-04-04
NZ525854A (en) 2004-06-25
EP1341531A2 (en) 2003-09-10
HUP0301842A3 (en) 2010-03-29
ES2278804T3 (es) 2007-08-16
ZA200303789B (en) 2004-08-16
AR035927A1 (es) 2004-07-28
PL362688A1 (en) 2004-11-02
DK1341531T3 (da) 2007-05-14
MY134559A (en) 2007-12-31
IL155960A (en) 2009-06-15

Similar Documents

Publication Publication Date Title
HRP20030383B1 (en) Lactam compound
EA200300050A1 (ru) Гликопептидфосфонатные производные
ATE403429T1 (de) Spiropyrazol-verbindungen
EA199900373A2 (ru) Фармацевтические композиции
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
BR0116217A (pt) Quinolonas antimicrobianas, composição farmacêutica, bem como aplicação farmacêutica das referidas quinolonas
NO974321L (no) Nodulisporsyrederivater
RS50229B (sr) Analozi vitamina d3
MXPA03009602A (es) Analogos de nociceptina.
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
DE602004023105D1 (de) HERSTELLUNG VON 4,5-DIALKYL-3-ACYLPYRROL-2-CARBONS ANSCHLIEßENDE ACYLIERUNG
BR9902084A (pt) Heterociclos.
ATE257139T1 (de) Ein (1'r,2's,5'r)-3-l-menthoxypropan-1-ol, das eine kühlende empfindung erzeugt
DK1204659T3 (da) Serotonerge benzofuraner
TR199901017A2 (xx) B�cek ilac� terkibi.
MXPA02011234A (es) Nuevas bases de oxidacion 2,5-diaminopiridina utiles para el tinte de las fibras queratinicas.
DK0931082T3 (da) Nodulisporinsyrederivater
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate
ATE367375T1 (de) Alkylsulfanylbenzole als duftstoffe
PL365687A1 (en) Novel trioxepan compounds
GT199900160A (es) Compuestos plaguicidas de bis-oxima.
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων
RS50412B (sr) Derivati tiazofurina

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20131029

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20141105